Tenpoint Therapeutics’ YUVEZZI, projected to launch in the US in Q2 2026, represents the first fixed-dose combination eye drop developed to enhance near vision through pupil modulation with once-daily ...
The completion of the full BLA submission is anticipated in early 2026 and is eligible for priority review under the program’s fast-track designation. Today Nanoscope Therapeutics announced its ...
Two FDA-approved geographic atrophy treatments show significant patient dropout, with 45% discontinuation by 18 months, driven by baseline vision, CNV, and lack of immediate visual improvement. In a ...
EyePoint Pharmaceuticals completes enrollment for the LUCIA trial, advancing DURAVYU's potential as a new treatment for wet AMD. EyePoint Pharmaceuticals recently announced the completion of ...
This follows successful Phase 1 results, which demonstrated a favorable safety profile for BI 771716 across both single and multiple intravitreal doses. CDR-Life under its collaboration and licensing ...
As part of the Johns Hopkins Wilmer Eye Institute’s MACULA 2025 and the 5th Annual Retina Festival, Christina Y. Weng, MD, MBA, gave a presentation titled “Home Monitoring for Age-Related Macular ...
During the EURETINA session, Stela Vujosevic, MD, PhD, FEBO, posed questions about the current staging for diabetic macular edema and diabetic retinopathy. As imaging modalities improve, so do ...
The Vision Council’s Q3 Provider Insights study shows the sentiments of eye care providers nationwide as they manage practices and patient care. The Vision Council has released the results of their ...
The trial is expected to close randomization in early December 2024. More than 300 patients have been randomized in the SOL-1 Phase 3 trial for OTX-TKI (AXPAXLI, axitinib intravitreal implant). The ...
This device is designed to assist healthcare professionals in analyzing fundus images for the early detection of key retinal conditions. Diagnos Inc. will file for US Food and Drug Administration (FDA ...
Alexander Fein, MD, spoke with the Eye Care Network to share how to approach a patient presenting with transient vision loss, what this type of vision loss can mean, and what additional testing might ...
Data show promising early improvements in low luminance visual acuity, a key measure of visual function. Beacon Therapeutics presented 3-month interim safety and efficacy data from the Phase 2 DAWN ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results